A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma.

KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA), but remains an intractable pharmacological target. Consequently, defining RAS effector pathway(s) required for PDA initiation and maintenance is critical to improve treatment of this disease. Here we demonstrate that expression o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Collisson, Eric A., Trejo, Christy, Silva, Jillian, Gu, Shenda, Korkola, James E., Heiser, Laura, Charles, Roch-Philippe, Rabinovich, Brian A., Hann, Byron, Dankort, David, Spellman, Paul T., Phillips, Wayne, Gray, Joe W., McMahon, Martin
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425446/
https://ncbi.nlm.nih.gov/pubmed/22628411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0347
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items